VeriStrat was applied retrospectively to a subset of the patient population from BR.21.
The NCIC BR.21 study compared erlotinib to placebo in previously treated patients with non-small cell lung cancer (NSCLC).1
BR.21 has been extensively analyzed to determine if biomarkers can predict patient outcomes to erlotinib therapy.
VeriStrat retrospective analysis of BR.21
The retrospective VeriStrat analysis involved 441 of 731 patients from the BR.21 Trial and classified patients as VeriStrat Good or VeriStrat Poor.2
VeriStrat Good patients treated with erlotinib had a significantly better overall survival than VeriStrat Poor patients treated with erlotinib.2
When treated with erlotinib, VeriStrat Good patients had a median overall survival of 10.5 months as compared to placebo.2
VeriStrat Poor patients had no statistically significant improvement in overall survival when treated with erlotinib as compared to placebo.2
VeriStrat is predictive of objective response rate and disease control rate in patients treated with erlotinib .2
VeriStrat status is independent of tissue markers.
VeriStrat is a unique test that identifies patients who are likely to benefit from erlotinib therapy, as well as those not likely to benefit.
1 Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
2 Carbone D, 2nd European Lung Cancer Conference, April 2010.
3 Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:4268-4275.
